TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07054099: A Phase III, Double-blind, Randomized, Multicenter, Multinational, Active-controlled, Non-inferiority Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Chil

Sponsor: GC Biopharma Corp · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 474 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,676,800

Rescue Site Savings

+$10,336,890

Unlock Full NCT07054099 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07054099 Rescue Dossier →